Save
Email
Print
ShareMar. 22, 2010 — The TRAIL ligand is a promising anticancer agent that preferentially kills tumor cells without apparent damage to healthy cells. Many cancers exhibit resistance to TRAIL, however, thus limiting its therapeutic potential.
According to a study in the March 22 issue of the Journal of Cell Biology, small molecules known to block Mcl-1 (induced myeloid leukemia cell differentiation protein) might represent a suitable means to overcome TRAIL resistance.
Researchers know that TRAIL-induced cell death entirely depends on the presence of Bax, which is a member of the proapoptotic Bcl-2 family of proteins and is often lost in tumor cells for various reasons. Despite the expression of Bak, another protein that promotes dell death, Bax-deficient cells are resistant to TRAIL-induced death.
Peter Daniel (Humboldt University, Germany) and colleagues investigate the role of two Bcl-2 proteins -- Mcl-1 and Bcl-xL -- that keep Bak in check. The team's findings show that blocking Mcl-1 but not Bcl-xL overcame resistance to TRAIL-induced cell death in bax-deficient cells and enabled TRAIL to activate Bak. Blocking Bak inhibitors like Mcl-1 appears to be a promising strategy in limiting the resistance of cancers to TRAIL.
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by Rockefeller University Press, via EurekAlert!, a service of AAAS.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
- B. Gillissen, J. Wendt, A. Richter, A. Richter, A. Muer, T. Overkamp, N. Gebhardt, R. Preissner, C. Belka, B. Dorken, P. T. Daniel. Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. The Journal of Cell Biology, 2010; 188 (6): 851 DOI: 10.1083/jcb.200912070
Note: If no author is given, the source is cited instead.
more 
